IN2014DN03464A - - Google Patents

Download PDF

Info

Publication number
IN2014DN03464A
IN2014DN03464A IN3464DEN2014A IN2014DN03464A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A IN 3464DEN2014 A IN3464DEN2014 A IN 3464DEN2014A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A
Authority
IN
India
Prior art keywords
providing neuroprotection
stroke
mirna
administering
variant
Prior art date
Application number
Other languages
English (en)
Inventor
Suh hang H JUO
Yung Song Wang
Hsin Yun Cheng
Original Assignee
Dcb Usa Llc
Univ Kaohsiung Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcb Usa Llc, Univ Kaohsiung Medical filed Critical Dcb Usa Llc
Publication of IN2014DN03464A publication Critical patent/IN2014DN03464A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
IN3464DEN2014 2011-11-03 2012-11-05 IN2014DN03464A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555152P 2011-11-03 2011-11-03
PCT/US2012/063604 WO2013067531A2 (en) 2011-11-03 2012-11-05 Methods of using microrna 195 in providing neuroprotection

Publications (1)

Publication Number Publication Date
IN2014DN03464A true IN2014DN03464A (enrdf_load_html_response) 2015-06-05

Family

ID=48193054

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3464DEN2014 IN2014DN03464A (enrdf_load_html_response) 2011-11-03 2012-11-05

Country Status (7)

Country Link
US (1) US9315812B2 (enrdf_load_html_response)
EP (1) EP2773381B1 (enrdf_load_html_response)
JP (1) JP5888572B2 (enrdf_load_html_response)
CN (1) CN104080910A (enrdf_load_html_response)
IN (1) IN2014DN03464A (enrdf_load_html_response)
TW (1) TWI462741B (enrdf_load_html_response)
WO (1) WO2013067531A2 (enrdf_load_html_response)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916989A1 (en) * 2013-06-28 2014-12-31 London Health Sciences Centre Research Inc. Inhibition of microrna for treatment of sepsis
CN106474549B (zh) 2016-11-21 2019-05-03 南通大学 MicroRNA基因介导的新型组织工程化神经的构建及其在修复神经缺损的应用
CN110087638A (zh) 2016-12-14 2019-08-02 中国医药大学 微小rna-195组合物及其在眼科疾病中的应用
WO2021158476A1 (en) * 2020-02-03 2021-08-12 Rutgers, The State University Of New Jersey Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof
WO2022033529A1 (zh) * 2020-08-12 2022-02-17 洪明奇 Sema3d拮抗剂在预防或治疗神经退行性疾病以及延长寿命中的用途
CN113599540B (zh) * 2021-05-27 2023-05-23 山西医科大学 miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用
CN113308535A (zh) * 2021-06-11 2021-08-27 中国人民解放军空军军医大学 一种基于血清外泌体miRNA的PD诊断及分期试剂盒
CN116590403B (zh) * 2023-05-17 2024-11-22 华中科技大学同济医学院附属同济医院 血浆外泌体microRNA novel-3及其拮抗剂和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
EP1713938A2 (en) * 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US20100298407A1 (en) * 2007-01-17 2010-11-25 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
WO2009062169A2 (en) * 2007-11-09 2009-05-14 The Board Of Regents Of The University Of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
EP2112235A1 (en) * 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
EP2239675A1 (en) * 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease
WO2010151640A2 (en) * 2009-06-24 2010-12-29 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug

Also Published As

Publication number Publication date
EP2773381A2 (en) 2014-09-10
CN104080910A (zh) 2014-10-01
EP2773381B1 (en) 2020-06-03
WO2013067531A2 (en) 2013-05-10
US9315812B2 (en) 2016-04-19
WO2013067531A3 (en) 2014-07-03
EP2773381A4 (en) 2015-07-08
JP5888572B2 (ja) 2016-03-22
US20140294943A1 (en) 2014-10-02
JP2014533248A (ja) 2014-12-11
TW201322987A (zh) 2013-06-16
TWI462741B (zh) 2014-12-01

Similar Documents

Publication Publication Date Title
IN2014DN03464A (enrdf_load_html_response)
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
MX364495B (es) Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos.
MX368649B (es) Mezclas fungicidas de penflufén.
RS61892B1 (sr) Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
EP2812794A4 (en) DYNAMIC CODE INJECTION IN A PROCESS IN PROGRESS
IN2012MU03723A (enrdf_load_html_response)
PL2763527T3 (pl) Sposób obróbki grzybobójczej odpornych szczepów przy użyciu jednego lub więcej olejków eterycznych
EP2677068A4 (en) METHOD FOR SURFACE TREATMENT OF A METALLIC ELEMENT AND METAL ELEMENT THUS OBTAINED
ZA201306990B (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
PL2997173T3 (pl) Sposób wytwarzania stali powleczonej cynkiem do utwardzania w procesie tłoczenia na gorąco
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
EP2758780A4 (en) METHOD OF TREATING MULTIPLE SCLEROSIS
IN2015DN02292A (enrdf_load_html_response)
ZA201404327B (en) Composition comprising block cocondensates of propylfunctional alkaline siliconates and silicates, and method for the production thereof
IN2014DN08777A (enrdf_load_html_response)
EP2739332A4 (en) STOPPERS / PISTONS FOR CARCASES OF A SPRAYING CARPULAR ARRANGEMENT
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
ZA201408975B (en) Method of treating scedosporium spp. infection
HUE038149T2 (hu) Eljárás acél kezelésére
RS57133B1 (sr) Kompozicija za tretman poremećaja hipoaktivno umanjenje seksualne želje
PL2768527T3 (pl) Wieloważna szczepionka przeciw CBV do zapobiegania lub leczenia cukrzycy typu 1
IN2013CH05865A (enrdf_load_html_response)